Management of Abnormal TAPSE Indicating Right Ventricular Dysfunction

Defining Abnormal TAPSE

The European Society of Cardiology recommends that a TAPSE measurement <17 mm indicates right ventricular systolic dysfunction and warrants further evaluation 1
Normal TAPSE is 24 ± 3.5 mm, with values below this threshold suggesting impaired RV longitudinal function 1
A TAPSE <16 mm specifically indicates significant RV pressure overload and is used as a cutoff in acute conditions like pulmonary embolism 2

The European Heart Society suggests that in cases of acute pulmonary embolism, look for dilated RV with RV/LV ratio >1.0, paradoxical septal motion, McConnell sign, and distended IVC 2
For pulmonary hypertension, assess RVSP; if >45 mmHg with TAPSE <1.6 cm, right heart catheterization is required 4
In cases of severe tricuspid regurgitation, TAPSE may be less accurate and should be interpreted cautiously 5, 6

The European Society of Cardiology states that TAPSE alone is insufficient for management decisions and must be integrated with multiple parameters, including RV fractional area change (RVFAC), RV dimensions, tissue Doppler S' velocity, and RV free wall strain 5, 6
RVFAC: Normal >32%; <35% indicates dysfunction 1, 6
RV dimensions: Mid-RV dimension >33 mm, RV end-diastolic area >28 cm², or RV end-systolic area >16 cm² suggest RV dilation 6
Tissue Doppler S' velocity: <9.5 cm/s at the tricuspid lateral annulus indicates RV dysfunction 1
RV free wall strain: Values >-20% suggest dysfunction 1

A TAPSE <16 mm with RVSP >45 mmHg mandates cardiology referral for right heart catheterization 4
Combination of TAPSE <16 mm, RV/LV ratio >1.0, and dilated non-collapsing IVC suggests acute RV failure 2, 3

The European Society of Cardiology recommends treating the primary etiology while monitoring for clinical decompensation, such as anticoagulation for pulmonary embolism or PAH-specific therapy for pulmonary hypertension 2, 5, 6
For severe TR, surgical intervention may be indicated if symptomatic with progressive RV dysfunction 5, 6

Serial TAPSE measurements are less suitable for monitoring due to reproducibility issues compared to baseline assessment 7
Post-intervention echocardiographic surveillance at 3 months (or earlier if clinically indicated) is recommended for patients with cardiac dysfunction or valvular disease 4
Consider RVEF by cardiac MRI for more accurate serial assessment if available, as it is the gold standard for RV function 7, 8